M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?

Scarpa, Miriam; Hesse, Sarah; Bradley, Sophie J

Scarpa, Miriam; Hesse, Sarah; Bradley, Sophie J.

Afiliação

Scarpa M; The Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Hesse S; The Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Bradley SJ; The Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom. Electronic address: sophie.bradley@glasgow.ac.uk.

Adv Pharmacol ; 88: 277-310, 2020.

Article em En | MEDLINE | ID: mdl-32416870

Assuntos

Doença de Alzheimer/tratamento farmacológico; Doença de Alzheimer/metabolismo; Terapia de Alvo Molecular; Receptor Muscarínico M1/metabolismo; Regulação Alostérica; Animais; Descoberta de Drogas; Humanos; Agonistas Muscarínicos/uso terapêutico; Receptor Muscarínico M1/agonistas

Palavras-chave

Allosteric; Alzheimer's disease; Cognition; Disease modifying; Muscarinic; Neurodegeneration

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptor Muscarínico M1 / Terapia de Alvo Molecular / Doença de Alzheimer Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google